Prescribing information

 

   

Durable five-year survival benefit1

TAFINLAR (dabrafenib) in combination with MEKINIST (trametinib) is indicated in adults for the treatment of BRAF V600-positive unresectable or metastatic melanoma.2,3

Landmark data demonstrate TAFINLAR + MEKINIST achieves durable overall survival and long-term progression-free survival benefits versus BRAF inhibitor alone that are maintained over five years. Treatment with TAFINLAR + MEKINIST is also associated with a well-established safety profile.1

Please select an option below to find out more about patient management, or the efficacy and safety profile of TAFINLAR + MEKINIST for the treatment of adult BRAF V600-positive metastatic melanoma.

References

  1. Robert C, et al. N Engl J Med 2019; 381:626–636.
  2. TAFINLAR (dabrafenib) Summary of Product Characteristics.
  3. MEKINIST (trametinib) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | December 2020 | 100902
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]